Nephrogenic systemic fibrosis

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Nephrogenic systemic fibrosis (NSF) is a dermatological fibrosing disease with potential systemic manifestations resulting in mild to severe symptoms including joint contractures. NSF can be lethal in a subset of cases. It has been recently observed that almost all patients with NSF have had severe renal insufficiency and have received prior administrations of gadolinium-based contrast agents (GBCA). This review will focus on the specific evidence from a retrospective study performed at our center in combination with the general experience available. Conclusions summarize our current understanding of NSF. Recommendations are provided for use of GBCA in clinical MRI practice. Conclusions and recommendations include that the risk of inducing NSF is related to higher-dose administrations of GBCA and that there are differences in risk related to differences in gadolinium-chelate formulation, with the highest relative risk associated with gadodiamide (Omniscan, Nycomed Amersham, GE Healthcare, Piscataway, N.J.).

Original languageEnglish (US)
JournalPediatric Radiology
Volume38
Issue number1 SUPPL.
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Nephrogenic Fibrosing Dermopathy
gadodiamide
Gadolinium
Contrast Media
Contracture
Renal Insufficiency
Retrospective Studies
Joints
Delivery of Health Care

Keywords

  • Children
  • Gadolinium
  • MRI
  • Nephrogenic systemic fibrosis
  • Renal insufficiency

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Pediatrics, Perinatology, and Child Health
  • Radiological and Ultrasound Technology

Cite this

Nephrogenic systemic fibrosis. / Martin, Diego R.

In: Pediatric Radiology, Vol. 38, No. 1 SUPPL., 01.2008.

Research output: Contribution to journalArticle

@article{9bf50d974ebb4b81a41cb58a38fce0df,
title = "Nephrogenic systemic fibrosis",
abstract = "Nephrogenic systemic fibrosis (NSF) is a dermatological fibrosing disease with potential systemic manifestations resulting in mild to severe symptoms including joint contractures. NSF can be lethal in a subset of cases. It has been recently observed that almost all patients with NSF have had severe renal insufficiency and have received prior administrations of gadolinium-based contrast agents (GBCA). This review will focus on the specific evidence from a retrospective study performed at our center in combination with the general experience available. Conclusions summarize our current understanding of NSF. Recommendations are provided for use of GBCA in clinical MRI practice. Conclusions and recommendations include that the risk of inducing NSF is related to higher-dose administrations of GBCA and that there are differences in risk related to differences in gadolinium-chelate formulation, with the highest relative risk associated with gadodiamide (Omniscan, Nycomed Amersham, GE Healthcare, Piscataway, N.J.).",
keywords = "Children, Gadolinium, MRI, Nephrogenic systemic fibrosis, Renal insufficiency",
author = "Martin, {Diego R}",
year = "2008",
month = "1",
doi = "10.1007/s00247-007-0589-8",
language = "English (US)",
volume = "38",
journal = "Pediatric Radiology",
issn = "0301-0449",
publisher = "Springer Verlag",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Nephrogenic systemic fibrosis

AU - Martin, Diego R

PY - 2008/1

Y1 - 2008/1

N2 - Nephrogenic systemic fibrosis (NSF) is a dermatological fibrosing disease with potential systemic manifestations resulting in mild to severe symptoms including joint contractures. NSF can be lethal in a subset of cases. It has been recently observed that almost all patients with NSF have had severe renal insufficiency and have received prior administrations of gadolinium-based contrast agents (GBCA). This review will focus on the specific evidence from a retrospective study performed at our center in combination with the general experience available. Conclusions summarize our current understanding of NSF. Recommendations are provided for use of GBCA in clinical MRI practice. Conclusions and recommendations include that the risk of inducing NSF is related to higher-dose administrations of GBCA and that there are differences in risk related to differences in gadolinium-chelate formulation, with the highest relative risk associated with gadodiamide (Omniscan, Nycomed Amersham, GE Healthcare, Piscataway, N.J.).

AB - Nephrogenic systemic fibrosis (NSF) is a dermatological fibrosing disease with potential systemic manifestations resulting in mild to severe symptoms including joint contractures. NSF can be lethal in a subset of cases. It has been recently observed that almost all patients with NSF have had severe renal insufficiency and have received prior administrations of gadolinium-based contrast agents (GBCA). This review will focus on the specific evidence from a retrospective study performed at our center in combination with the general experience available. Conclusions summarize our current understanding of NSF. Recommendations are provided for use of GBCA in clinical MRI practice. Conclusions and recommendations include that the risk of inducing NSF is related to higher-dose administrations of GBCA and that there are differences in risk related to differences in gadolinium-chelate formulation, with the highest relative risk associated with gadodiamide (Omniscan, Nycomed Amersham, GE Healthcare, Piscataway, N.J.).

KW - Children

KW - Gadolinium

KW - MRI

KW - Nephrogenic systemic fibrosis

KW - Renal insufficiency

UR - http://www.scopus.com/inward/record.url?scp=37549037896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549037896&partnerID=8YFLogxK

U2 - 10.1007/s00247-007-0589-8

DO - 10.1007/s00247-007-0589-8

M3 - Article

C2 - 18071694

AN - SCOPUS:37549037896

VL - 38

JO - Pediatric Radiology

JF - Pediatric Radiology

SN - 0301-0449

IS - 1 SUPPL.

ER -